Nitrase Therapeutics
Harry Ischiropoulos, Ph.D., is the Gisela and Dennis Alter research professor of Pediatrics and Systems Pharmacology and Translational Therapeutics at the Children’s Hospital of Philadelphia Research Institute and the Perelman School of Medicine at the University of Pennsylvania. His laboratory investigates the biological chemistry and signaling pathways of nitric oxide in the cardiovascular and neuronal systems using mass spectroscopy-based technologies. Dr. Ischiropoulos has authored 195 publications and is the recipient of several professional awards including an Established Investigator award from the American Heart Association. He served on several NIH review panels and advisory committees. He was the president for the Society for Free Radical Biology and Medicine and served on the board of directors for the Federation of American Societies for Experimental Biology. He was an editor for the journal Free Radical Biology and Medicine and chaired the Gordon Research Conferences on Oxygen Radicals (2014) and on Nitric Oxide (2015). Dr. Ischiropoulos received a BS in chemistry from Wagner College, an MS in pathology and a Ph.D. in experimental pathology from New York Medical College.
This person is not in the org chart
This person is not in any offices
Nitrase Therapeutics
1 followers
Nitrase Therapeutics is a pioneering biopharmaceutical company deploying its unique NITROME platform to unlock the therapeutic potential of nitrases, a new class of enzymes that it discovered, to develop a pipeline of therapies against a broad variety of diseases. The medicines that Nitrase Therapeutics is developing will target these enzymes and potentially help slow or halt the progression of a wide variety of diseases in which nitrases and nitro-substrates play a role, including Parkinson’s and cancer. Nitrase Therapeutics (under the former name Nitrome Biosciences) has been widely recognized and has won multiple awards including the prestigious Target Advancement grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF).